Who are lopinavir/ritonavir and raltegravir's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lopinavir-ritonavir-and-raltegravir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

lopinavir/ritonavir and raltegravir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

lopinavir/ritonavir and raltegravir (lopinavir/ritonavir and raltegravir) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor (lopinavir/ritonavir) and integrase strand transfer inhibitor (raltegravir). Area: Infectious Disease.

marketed Protease inhibitor (lopinavir/ritonavir) and integrase strand transfer inhibitor (raltegravir) HIV protease (lopinavir/ritonavir) and HIV integrase (raltegravir) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

lopinavir/ritonavir and raltegravir (lopinavir/ritonavir and raltegravir) — Saint Michael's Medical Center. Lopinavir/ritonavir inhibits HIV protease to block viral replication, while raltegravir inhibits HIV integrase to prevent viral DNA integration into the host genome.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
lopinavir/ritonavir and raltegravir TARGET	lopinavir/ritonavir and raltegravir	Saint Michael's Medical Center	marketed	Protease inhibitor (lopinavir/ritonavir) and integrase strand transfer inhibitor (raltegravir)	HIV protease (lopinavir/ritonavir) and HIV integrase (raltegravir)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor (lopinavir/ritonavir) and integrase strand transfer inhibitor (raltegravir) class)

Saint Michael's Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). lopinavir/ritonavir and raltegravir — Competitive Intelligence Brief. https://druglandscape.com/ci/lopinavir-ritonavir-and-raltegravir. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab